Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

The FDA has officially placed two of Intellia’s Phase III studies under clinical hold after the biotech reported earlier this ...

Intellia Therapeutics (NASDAQ:NTLA) shares plummeted 50% on Monday after the company announced a temporary halt to patient dosing and screening in its Phase 3 trials of nex-z, citing a serious ...

Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide. This prevalent condition is also linked to other metabolic disorders, including type 2 ...

Tulane University researchers have developed an enhanced CRISPR-based tuberculosis test that works with a simple tongue swab, a potential breakthrough that could allow easier, community-based ...

More than 10 million people develop tuberculosis (TB) each year, yet about 40% go undiagnosed. The main culprit is reliance on sputum-based testing, which many patients—particularly those who are ...